Optometry: Open Access
Open Access

Macular degeneration; Age-related macular degeneration; AMD; Vision loss; Risk factors; symptoms; Treatment options; Diagnostics; Anti-VEGF therapy; Photodynamic therapy

Introduction

Macular degeneration is a chronic, progressive disease that affects the macula, the central part of the retina responsible for sharp, central vision. It is the leading cause of irreversible vision loss among individuals aged 50 and older in developed countries, with a significant impact on quality of life and daily activities [1]. The prevalence of macular degeneration is expected to rise with the aging population, making it a major public health concern. Understanding the underlying mechanisms of AMD and its risk factors is crucial for early detection, timely intervention, and effective management of this debilitating condition [2].

Causes and risk factors

The exact cause of macular degeneration is not fully understood, but several factors are believed to contribute to its development. Age is the primary risk factor, with the incidence of AMD increasing significantly after the age of 50. Genetics also play a crucial role, as certain gene variants have been associated with an increased risk of developing AMD. Other risk factors include smoking, obesity, hypertension, and a diet low in antioxidants and omega-3 fatty acids [3,4]. Additionally, Caucasians and individuals with a family history of AMD are at higher risk of developing the disease.

Symptoms and clinical presentation

Macular degeneration typically presents with gradual, painless vision loss in the central field of vision. Early symptoms may include difficulty reading, recognizing faces, or performing tasks that require detailed vision. As the disease progresses, patients may experience a blurry or distorted central vision, often described as seeing straight lines as wavy or crooked. In advanced stages, central vision loss can significantly impair a person's ability to drive, read, or perform other daily activities [5].

Types of macular degeneration

There are two main types of AMD: dry AMD and wet AMD. Dry AMD, also known as non-neovascular AMD, is characterized by the accumulation of drusen, yellow deposits beneath the retina. It is the most common form of AMD, accounting for about 80-90% of all cases. Dry AMD progresses slowly and is usually less severe than wet AMD [6]. However, in some cases, it can lead to geographic atrophy, a severe form of dry AMD that results in the loss of retinal pigment epithelium (RPE) cells and photoreceptors, causing irreversible vision loss [7]. Wet AMD, also known as neovascular AMD, is characterized by the growth of abnormal blood vessels beneath the retina. These vessels are fragile and prone to leakage, leading to the accumulation of fluid and blood in the macula. Wet AMD is less common than dry AMD but accounts for the majority of severe vision loss cases. Without prompt treatment, wet AMD can rapidly progress and cause permanent damage to the macula, resulting in severe central vision loss [8].

Diagnosis

Early diagnosis of AMD is crucial for preserving vision and preventing further progression of the disease. A comprehensive eye examination, including visual acuity testing, dilated fundus examination, and retinal imaging, is essential for detecting the presence of drusen, pigment changes, or other signs of AMD. Optical coherence tomography (OCT) and fluorescein angiography are imaging techniques commonly used to evaluate the structural and functional changes in the retina and choroid, aiding in the diagnosis and monitoring of AMD.

Treatment options

Treatment for AMD depends on the type and stage of the disease. Currently, there is no cure for AMD, but several treatment options are available to slow its progression and manage its symptoms. In the early stages of dry AMD, lifestyle modifications, such as quitting smoking, eating a healthy diet rich in antioxidants and omega-3 fatty acids, and maintaining a healthy weight and blood pressure, may help reduce the risk of progression [9]. In advanced stages, nutritional supplements, such as vitamins C and E, zinc, copper, and lutein/zeaxanthin, known as the AREDS2 formula, may be recommended to slow vision loss. For wet AMD, the mainstay of treatment is anti-vascular endothelial growth factor (anti-VEGF) therapy, which involves injecting anti-VEGF drugs directly into the eye to inhibit the growth of abnormal blood vessels and reduce leakage. Photodynamic therapy (PDT) may also be used in some cases to destroy abnormal blood vessels. In advanced cases of wet AMD, low vision rehabilitation services, such as magnifiers, telescopic lenses, and vision therapy, may be helpful in improving visual function and quality of life [10].

Conclusion

Macular degeneration is a complex and multifactorial disease that poses significant challenges to patients, caregivers, and healthcare providers. Early detection, timely intervention, and close monitoring are essential for preserving vision and maintaining quality of life in patients with AMD. Continued research efforts aimed at better understanding the pathogenesis of AMD and developing novel treatment modalities are crucial for improving outcomes and reducing the burden of this sight-threatening condition. A multidisciplinary approach involving ophthalmologists, optometrists, primary care physicians, and other healthcare professionals is essential for providing comprehensive care to patients with AMD and optimizing their visual outcomes.

1. Verma JP, Jaiswal DK (2016) Book review: advances in biodegradation and bioremediation of industrial waste. Front Microbiol 6:1-2.

Indexed at, Google Scholar

2. Frutos FJ, Pérez R, Escolano O, Rubio A, Gimeno A, et al. (2012) Remediation trials for hydrocarbon-contaminated sludge from a soil washing process: evaluation of bioremediation technologies. J Hazard Mater 199:262-27.

Indexed at, Google Scholar, Crossref

3. Frutos FJ, Escolano O, García S, Babín M, Fernández MD (2010) Bioventing remediation and ecotoxicity evaluation of phenanthrene-contaminated soil. J Hazard Mater 183: 806-813.

Indexed at, Google Scholar, Crossref

4. Sui H, Li X (2011) Modeling for volatilization and bioremediation of toluene-contaminated soil by bioventing. Chin J Chem Eng 19: 340-348.

Indexed at, Google Scholar, Crossref

5. Gomez F, Sartaj M (2013) Field scale ex situ bioremediation of petroleum contaminated soil under cold climate conditions. Int Biodeterior Biodegradation 85: 375-382.

Google Scholar, Crossref

6. Khudur LS, Shahsavari E, Miranda AF, Morrison PD, Nugegoda D, et al. (2015) Evaluating the efficacy of bioremediating a diesel-contaminated soil using ecotoxicological and bacterial community indices. Environ Sci Pollut Res 22: 14819.

Indexed at, Google Scholar, Crossref

7. Whelan MJ, Coulon F, Hince G, Rayner J, McWatters R, et al. (2015) Fate and transport of petroleum hydrocarbons in engineered biopiles in polar regions. Chemosphere 131: 232-240.

Indexed at, Google Scholar, Crossref

8. Dias RL, Ruberto L, Calabró A, Balbo AL, Panno MT, et al. (2015) Hydrocarbon removal and bacterial community structure in on-site biostimulated biopile systems designed for bioremediation of diesel-contaminated Antarctic soil. Polar Biol 38: 677-687.

Google Scholar, Crossref

9. Sanscartier D, Zeeb B, Koch I, Reimer (2009) Bioremediation of diesel-contaminated soil by heated and humidified biopile system in cold climates. Cold Reg Sci Technol 55: 167-173.

Google Scholar, Crossref

10. Coulon F, Awadi M, Cowie W, Mardlin D, Pollard S, et al. (2010) When is a soil remediated? Comparison of biopiled and windrowed soils contaminated with bunker-fuel in a full-scale trial. Environ Pollut 158: 3032-3040.

Indexed at, Google Scholar, Crossref